J&J Talc Settlement Blasted by Ex-FDA Head Over Asbestos Testing
A Johnson & Johnson unit working to resolve massive cancer litigation in bankruptcy court was accused by a former head of the ...
FDA recall notice details J&J pause of Varipulse
Four of the 132 patients treated with Varipulse in the first two months of the U.S. launch had a form of stroke shortly after surgery.
Johnson & Johnson: No More Tears, Just Gains In Intra-Cellular Acquisition
JNJ's $14B acquisition of ITCI bolsters its portfolio with Caplyta, showing strong sales and patent protection until 2033.
Johnson & Johnson price target raised to $171 from $159 at BofA
BofA raised the firm’s price target on Johnson & Johnson (JNJ) to $171 from $159 and keeps a Neutral rating on the shares. For the last ...
J&J sues Samsung Bioepis over Stelara biosimilar
Johnson & Johnson sued Samsung Bioepis for allegedly breaching a contract agreement over its launch of a biosimilar to ...
Modern Healthcare13d
Robotic surgery gains ground inside hospitals
Medtech giants are doubling down on robotic surgery systems as hospitals see fewer complications and shorter stays.
Managed Healthcare Executive2d
Fresenius Kabi Launches Otulfi, the 4th Biosimilar of Stelara to Become Available
The FDA had approved Otulfi in September 2024 to treat Crohn’s disease, ulcerative colitis, psoriasis and active psoriatic arthritis. Information on pricing is not yet available.